ACHV — Achieve Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $81.86m
- $57.33m
Annual cashflow statement for Achieve Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.7 | -33.2 | -42.4 | -29.8 | -39.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.29 | 2.23 | 4.47 | 5.89 | 7.42 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.285 | 1.23 | 0.099 | -0.778 | 2.41 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -13.5 | -29.4 | -37.5 | -24.5 | -29.8 |
| Capital Expenditures | -0.017 | — | — | -0.021 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -21.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.017 | — | — | -0.021 | -21.6 |
| Financing Cash Flow Items | 27.9 | — | 19.1 | -0.25 | -0.114 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 32.7 | 36.6 | 19.3 | 15.3 | 48.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 19.2 | 7.17 | -18.3 | -9.22 | -2.82 |